Trial reportThe Journal of nutrition2025
Vitamin D Supplementation, Chronic Obstructive Lung Disease and Asthma Exacerbations, and Lung Function Decline.
Trial report in The Journal of nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01728571 (LungVITamin D and OmegA-3 Trial), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
LungVITamin D and OmegA-3 Trial
Who cites it
3 citing papers in PubMed.
- Vitamin D and Health Outcomes: State-of-the-Art Review of Triangulated Evidence and Ongoing Controversies.Current nutrition reports · 2026Review
- Importance of vitamin D in gastrointestinal health and disease.Frontiers in nutrition · 2026Review
- The promise of immunonutrition in pediatric pulmonary rehabilitation.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundIt remains unclear whether supplementation with vitamin D reduces risk of acute exacerbations of chronic obstructive lung disease (COPD) or asthma, major contributors to the world-wide burden of disease.
objectivesTo compare effects of vitamin D with placebo supplementation for the prespecified primary endpoints 1) acute exacerbations of COPD and 2) decline in pulmonary function measures of airflow obstruction. Prespecified secondary endpoints included asthma exacerbations and control.
methodsLung VITamin D and OmegA-3 TriaL (VITAL) is an ancillary study of VITAL, a United States nationwide, randomized, placebo-controlled trial with a 2-by-2 factorial design of vitamin D
resultsSupplementation with vitamin D was not associated with lower risk of any primary or secondary end point. Over the 5-y follow-up, the number of COPD exacerbations was 0.27/y in the vitamin D group and 0.25/y in the placebo group (rate ratio 1.10; 95% confidence interval, 0.93, 1.29). Over the 2-y follow-up, supplementation was not associated with slower decline (mL/y) in FEV
conclusionsSupplementation with vitamin D, compared with placebo, did not result in a lower rate of COPD exacerbations or improved pulmonary function in community-dwelling adults not selected for vitamin D deficiency. This trial was registered at Lung VITAL clinicaltrials.gov as NCT01728571 with Protocol ID 2010-P-000622 (https://prevention.cancer.gov/clinical-trials/clinical-trials-search/nct01728571).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.